Professor Hirofumi Sawa, Director of this IVReD, and Visiting Professor Akihiko Sato of the Clinical Development Department were involved in the development of Xocova, Japan’s first new coronavirus treatment. Taiwan Shionogi & Co., Ltd. received approval for a new drug application in Taiwan and signed a government stockpiling agreement. Please see the page below for details.